References
- Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune mediated inflammatory diseases: can biosimilars reduce access inequities? Front. Pharmacol. 2019;10:279.
- Declerck P, Danesi R, Petersel D, et al. The Language of Biosimilars: clarification, Definitions, and Regulatory Aspects. Drugs. 2017;77(6):671–677.
- Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford). 2017;56(suppl_4):iv14–29.
- Scavone C, Rafaniello C, Berrino L, et al. Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice. Pharmacol Res. 2017;126:138–142.
- Isaacs J, Gonçalves J, Strohal R, et al. The biosimilar approval process: how different is it? Considerations in Medicine. 2017;1(1):3–6.
- Krendyukov A, Schiestl M. Extrapolation concept at work with biosimilar: a decade of experience in oncology. ESMO Open. 2018;3(2):e000319.
- Sarzi-Puttini P, Marotto D, Caporali R, et al. Biosimilars vs originators: are they the same? Autoimmun Rev. 2019;18(12):102404.
- European Medicines Agency (EMA). Guideline On Similar Biological Medicinal Products. 2005. cited 2020 Jun 14. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-first-version_en.pdf
- Generics and Biosimilar initiative. Biosimilars approved in Europe. GaBi. [cited 2020 June 14]. Available from: http://gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
- US Food and Drug Administration (FDA). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. 2015. [cited 2020 Jun 14]. Available from https://www.fda.gov/media/82647/download.
- US Food and Drug Administration (FDA). Biosimilar product information. FDA-approved biosimilar products. [cited 2021 Jan 7]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information”https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
- Mikulic M. Branded vs. generic U.S. drug prescriptions dispensed 2005–2018. Statista. 2019. [cited 2020 Jun 14]. Available from https://www.statista.com/statistics/205042/proportion-of-brand-to-generic-prescriptions-dispensed/
- O’Callaghan J, Barry SP, Bermingham M, et al. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019;75(1):1–11.
- European Medicines Agency (EMA). Biosimilars in the EU. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. cited 2020 Jun 14.
- Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of Biosimilars: a European Perspective. BioDrugs. 2017;31(2):83–91.
- Renwick MJ, Smolina K, Gladstone EJ, et al. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17(1):e31–38. Policies with the context of interchangebility, physician prescribing, substitutabilit, pharmacist dispensing has been discuused.
- British Biosimilar Association. British Generics Manufacturers Association. [cited 2020 Jun 14]. Available from: https://britishbiosimilars.co.uk/
- Paul- Ehrlich- Institut. Position of Paul-Ehrlich-Institut Regarding the Use of Biosimilars. Cited 2020 Jan 7 Available from: https://www.pei.de/EN/medicinal-products/antibodies/mab/monoclonal-antibodies-node.html;jsessionid=B940B76F79DAA243505C6E35DAB8385D.intranet232?cms_tabcounter=1
- NoMA. Norwegian Medicines Agency proposes to amend the Pharmacy Act (In Norwegian, 2017). [Cited 2020 Jun 14]. Available from: https://legemiddelverket.no/nyheter/switching-between-a-reference-product-and-a-biosimilar
- Trifiro G, Marciano I, Ingrasciotta Y. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opin Biol Ther. 2018;18(3):309–315. Overview of positions of different regulatory bodies on interchangebility and substitution.
- US Food and Drug Administration (FDA) . Implementation of the Biologics Price Competition and Innovation Act of 2009. 2016. Cited 2020 Jun 14. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009
- U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Considerations in Demonstrating Interchangeability With a Reference Product-Guidance for Industry. 2019. [Cited 2020 Jun 14]. Cited 2020 Jun 14. Available from: https://www.fda.gov/media/124907/download
- US Food and Drug Administration (FDA). Purple Book: lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Cited 2020 Jun 14. Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or
- National conference on state legislatures. State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars. 2019. cited 2020 Dec 5. Available from: https://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx
- Gary M. Suggestions for state laws on biosimilar substitution. Mich. Telecomm. & Tech. L. Rev. 2018;24:253. Accessed. 2020. Available from: https://repository.law.umich.edu/mttlr/vol24/iss2/4
- Organization WH. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) . WHO Technical Report Series. 2009. Available from: https://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
- Allens Biosimilar White paper. Biologic medicines and biosimilars costs before caution-Australia’s unique approach to the interchangeability of biosimilars. Cited 2020 Jan 7. Available from: https://data.allens.com.au/pubs/pdf/healthcare/BiosimilarsWhitePaper-CostsbeforeCaution.pdf
- The Center for Biosimilars Staff. Mandated Switching to Biosimilars Begins in British Columbia, May Spread to Other Provinces. The Center for Biosimilars. Cited 2020 Jun 14. Available from: https://www.centerforbiosimilars.com/news/mandated-switching-to-biosimilars-begins-in-british-columbia-may-spread-to-other-provinces
- Welch AR, Biosimilar Development. How Canada built a framework for biosimilar transitions in its provinces. Cited 2021 Jan 7. Available from: https://www.biosimilardevelopment.com/doc/how-canada-built-a-framework-for-biosimilar-transitions-in-its-provinces-0001
- Murdoch B, Caulfield T. The Law and Ethics of Switching from Biologic to Biosimilar in Canada. J Can Assoc Gastroenterol. 2020;3(5):228–233.
- Nagai S, Yanagihara R, Kishioka Y. Japanese regulatory authority’s perspective on biosimilars. Lancet Oncol. 2015;16(3):E101.
- European Federation of Pharmaceutical Industries and Associations (EFPIA). Statement on Biosimilars by EFPIA Japan. 2017.[Cited 2020 Jun 14]. Available from: http://efpia.jp/link/Final_EFPIA_J_Biosimilar_Statement-revised_v6_ENG.pdf
- Suh SK, Park Y. Regulatory guideline for biosimilar products in Korea. Biologicals. 2011;39(5):336–338.
- Department of Biotechnology (DBT), Central Drugs Standard Control Organization (CDSCO). Guidelines on similar biologics: Regulatory requirements for marketing authorization in India. 2016. [Cited 2020 Jan 7]. Available from: http://nib.gov.in/NIB-DBT2016.pdf
- American College of Rheumatology (ACR). Position statement: therapeutic substitution 2019. Cited 2020 Jun 14. Available from https://www.rheumatology.org/Portals/0/Files/Therapeutic%20Substitution.pdf
- American Academy of Dermatology Association (AAD). Position Statement on Generic Therapeutic & Biosimilar Substitution. 2013. Cited 2020 Dec 5. Available from: https://server.aad.org/Forms/Policies/Uploads/PS/PS-Generic%20Therapeutic%20and%20%20Biosimilar%20Substitution.pdf?
- Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology Statement: biosimilars in Oncology. Journal of Clinical Oncology. 2018;36(12):1260–1265.
- Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016;1(6):e000142.
- European League Against Rheumatism (EULAR). Biosimilars position paper Updating position statement from the European League Against Rheumatism (EULAR) Standing Committee of People with Arthritis/Rheumatism in Europe (PARE). 2018. Accessed 2020 Dec 5. Available from: https://www.eular.org/myUploadData/files/biosimilars_paper_updated_2018_09_14_dw.pdf
- Danese S, Fiorino G, Raine T, et al. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update. Journal of Crohn’s and Colitis. 2017;11(1):26–34.
- Ridder L, Assa A, Bronsky J, et al. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: an Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68(1):144–153.
- International Diabetes Federation Europe (IDF). IDF Europe position paper on biosimilars in the treatment of people with diabetes. 2017. Cited 2020 Dec 5. Available from: https://www.idf.org/images/IDF_Europe_Position_on_Biosimilars.pdf
- Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106.
- A medicines for Europe. Positioning statements on physician- led switching for biosimilar medicines. 2020. cited 2021 Jan 7. Available from: https://www.medicinesforeurope.com/docs/M-Biosimilars-Overview-of-positions-on-physician-led-switching.pdf
- Argüelles Arias F, Hinojosa Del Val J, Vera Mendoza I. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease. Rev Esp Enferm Dig. 2018 Jun;110(6):407.
- Torres T, Ferreira A, Ferreira P, et al. Portuguese Position Paper on the Use of Biosimilars in Psoriasis. Acta Médica Portuguesa. 2016 Sep;29(9):574–577.
- Abad Hernandez MÁ, Andreu JL, Caracuel Ruiz MÁ, et al. Position paper from the Spanish Society of Rheumatology on biosimilar drugs. Reumatologia Clinica. 2015;11(5):269–278.
- Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmunity Reviews. 2014;13(7):751–755.
- Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33(12):2160–2172.
- Molinari A, Gewanter H, Reilly M, et al. SAT0570 Biologics and Biosimilars: do Physicians Understand The Differences? Ann Rheum Dis. 2016;75(Suppl 2):875.2–6.
- Ingrasciotta Y, Cutroneo PM, Marcianò I, et al. Safety of Biologics, Including Biosimilars: perspectives on Current Status and Future Direction. Drug Saf. 2018;41(11):1013–1022.
- Patel D, Park KT. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: quality Before Cost Savings. J Pediatr Gastroenterol Nutr. 2017;65(2):134–136.
- Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10(November):1–11.
- Peyrin-Biroulet L, Lonnfors S, Roblin X, et al. Patient Perspectives on Biosimilars: a Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations: table 1. J Crohns Colitis. 2017;11(1):128–133.
- Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74(5):655–661.
- Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018;14(9):739–749.
- Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963–1967.
- Cuellar S, McBride A, Medina P. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. American Journal of Health-System Pharmacy. 2019 Oct;76(21):1725–1738.
- GaBI. Biosimilars approved in Europe / General / Biosimilars / Home - GaBI Online - Generics and Biosimilars Initiative [Internet]. Generics & Biosimilars Inititaive. 2019 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe.
- FDA. Biosimilar Product Information. FDA- Approved Biosimilar Products. 2020 Accessed 14 June 2020. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
- Ebada MA, Elmatboly AM, Ali AS, et al. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. International Journal of Colorectal Disease. 2019;34(10):1633–1652.
- Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Alimentary Pharmacology & Therapeutics. 2019;49(1):31–40.
- Milassin Á, Fabian A, Molnar T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therapeutic Advances in Gastroenterology. 2019;12:1–11.
- Albshesh AA, Ben-Horin S. CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2019;19(10):971–978.
- Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin Biol Ther. 2018;18(6):633–640.
- EMA. Amgevita assessment report. 2017. Accessed 2020 Dec 5. Available from: https://www.ema.europa.eu/en/documents/assessment-report/amgevita-epar-public-assessment-report_en.pdf
- EMA. Hulio assessment report. 2018. Cited 2020 Dec 5. Available from: https://www.ema.europa.eu/en/documents/assessment-report/hulio-epar-public-assessment-report_en.pdf
- EMA. Amsparity assessment report. 2019. Cited 2020 Dec 5. Available from: https://www.ema.europa.eu/en/documents/assessment-report/amsparity-epar-public-assessment-report_en.pdf
- EMA. Hyrimoz assessment report. 2018. Accessed 2021 Jan 7. Available from: https://www.ema.europa.eu/en/documents/assessment-report/hyrimoz-epar-public-assessment-report_en.pdf
- EMA. Imraldi assessment report. 2017. Accessed 2021 Jan 7. Available from: https://www.ema.europa.eu/en/documents/assessment-report/imraldi-epar-public-assessment-report_en.pdf
- EMA. Idacio CHMP assessment report. 2019. Accessed 2021 Jan 7. Available from: https://www.ema.europa.eu/en/documents/assessment-report/idacio-epar-public-assessment-report_en.pdf
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research Application Number: 761024Orig1s000 Medical review(S). 2016. Accessed 2020 Dec 5. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000MedR.pdf
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research Application Number: 761071Orig1s000 Summary Review. 2017. Accessed 2020 Dec 5. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761071Orig1s000SumR.pdf.
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research Application Number: 761058Orig1s000 Medical Review(s). 2017. Cited 2021 Jan 7. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761058Orig1s000MedR.pdf
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research Application number: 761059Orig1s000 Multi-discipline review. 2018. Cited 2021 Jan 7. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761059Orig1s000MultidisciplineR.pdf
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research. Application number: 7611188Orig1s000 Multi-discipline review. 2018. Cited 2021 Jan 7. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000MultidisciplineR.pdf
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research. Application Number: 761154Orig1s000 Multi-discipline Review(s). 2019. Cited 2021 Jan 7 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761154Orig1s000MultidisciplineR.pdf
- Zhai MZ, Sarpatwri A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668–678.
- Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. . British Journal of Dermatology. 2017;177(6):1562–1574.
- Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–1687.
- Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(6):832–840.
- Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77(6):914–921.
- Hercogová J, Papp KA, Chyrok V, et al. AURIEL -PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316–326.
- Wiland P, Jeka S, Dokoupilová E, et al. Switching to biosimilar sdz-adl in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase iii, randomized, double-blind admyra study. BioDrugs. 2020 Dec;34(6):809–823.
- Edwards CJ, Monnet J, Ullmann M, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol. 2019;38(12):3381–3390.
- Genovese MC, Kellner H, Arai Y, et al. Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open. 2020;6(1):e000987.
- Su J, Li M, He L, et al. Comparison of the Efficacy and safety of adalimumab (humira) and the adalimumab biosimilar candidate (hs016) in chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-blind, parallel, phase iii clinical trial. BioDrugs. 2020 Jun;34(3):381–393.
- Blauvelt A, Lacour J-P, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. British Journal of Dermatology. 2018;179(3):623–631.
- Cohen S, Pablos JL, Pavelka K, et al. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):84.
- Ribaldone DG, Caviglia GP, Pellicano R, et al. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn�s disease: an observational study. Rev Esp Enferm Dig. 2020;112(3):195–200.
- Lukas M, Malickova K, Kolar M, et al. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: short-term Experience From a Single Tertiary Clinical Centre. J Crohns Colitis. 2020;14(7):915–919.
- Bruni C, Bitti R, Nacci F, et al. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. Clin Rheumatol. 2021;40 (1): 85-91.
- EMA. Benepali assessment report. 2015. Cited 2020 Dec 5. Available from: https://www.ema.europa.eu/en/documents/assessment-report/benepali-epar-public-assessment-report_en.pdf
- EMA. Erlezi assessment report. 2017. cited 2020 Dec 5. Available from: https://www.ema.europa.eu/en/documents/assessment-report/erelzi-epar-public-assessment-report_en.pdf
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research Application Number: 761066Orig1s000 Summary Review. 2019. Cited 2020 Dec 5. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761066Orig1s000SumR.pdf.
- FDA U.S. Food & Drug Administration. Center for Drug Evaluation and Research Application Number: 761042Orig1s000 Medical Review. 2016. Accessed 5 December 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1s000MedR.pdf.
- Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51–57.
- Matsuno H, Tomomitsu M, Hagino A, et al. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77(4):488–494.
- Yamanaka H, Kamatani N, Tanaka Y, et al. A comparative study to assess the efficacy, safety, and immunogenicity of ylb113 and the etanercept reference product for the treatment of patients with rheumatoid arthritis. Rheumatol Ther. 2020 Mar;7(1):149–163.
- Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21(1):130.
- Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–938.
- Park M-C, Matsuno H, Kim J, et al. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21(1):1–11.
- Bonifati C, Felice CD, Lora V, et al. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study. J Dermatolog Treat. 2020;31(7):687–691.
- Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4. Arthritis Rheumatol. 2018;70(9):1408–1418.
- Emery P, Vencovsky J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76(12):1986–1991.
- Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192–200.
- Codreanu C, Popescu CC, Mogoșan C, et al. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis – a comparison in a real-world national cohort. Biologicals. 2019;62:27–32.
- Madenidou AV, Jeffries A, Varughese S, et al. Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): a single-centre retrospective observational study in the UK and a review of the literature. J Rheumatol. 2019;30(Suppl 1):69–75.
- Pescitelli L, Lazzeri L, Di Cesare A, et al. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. Int J Clin Pharm. 2019;41(1):9–12.
- Felis-Giemza A, Chmurzynska K, Nałęcz-Janik J, et al. Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia/Rheumatology. 2019;57(5):257–263.
- Sigurdardottir V, Svard A. Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months – a cohort study with historical controls. Joint Bone Spine. 2019;86(4):529–530.
- Ditto MC, Parisi S, Priora M, et al. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Sci Rep. 2020;10(1):16178.
- Scherlinger M, Langlois E, Germain V. Acceptance Rate And Sociological Factors Involved In The Switch From Originator To Biosimilar Etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927–932.
- Bruni C, Gentileschi S, Pacini G, et al. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease. 2020;12:1759720X20964031.
- Ebbers HC, Pieper B, Issa A, et al. Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: a Systematic Review. Rheumatol Ther. 2019;6(3):317–338.
- Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478. Review on clinical outcomes of switching studies
- Barbier L, Ebbers HC, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020 March;108(4):734–755. Systematic review on switching studies between originator and biosimilars.
- Feagaween BG, Marabani M, Wu JJ, et al. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Advances in Therapy. 2020;37(11):4491–4518.